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INTRODUCTION
High density lipoprotein (HDL) particles are protein-lipid complexes that transport lipophilic molecules in the blood. Primarily known for their function in regulating cellular cholesterol concentrations through efflux of cholesterol out of cells and transport of cholesterol to the liver, HDL particles also perform a number of additional functions including immunomodulatory, antiinflammatory, anti-proteolytic, and other functions. [1] [2] [3] HDL particles are heterogeneous and undergo significant remodeling in vivo. 4 As many as 16 distinct HDL subclasses have been described, and based on their protein composition likely play distinct biological roles. 5 The proteomic composition of HDL particles is well known to affect HDL function and is altered in a variety of disease states. [6] [7] [8] Recently it has also been demostrated that HDL-associated proteins are highly glycosylated. 9 HDL-associated proteins enriched in HDL particles have a different site-specific glycosylation pattern from the same proteins found in plasma, 10 and their glycosylation may be useful for diagnostic purposes. 11 Importantly, key HDL proteins are differentially glycosylated in multiple disease states vs. healthy individuals, and site-specific glycosylation of HDL-associated proteins is associated with HDL's immunomodulatory capacity. 12 Apolipoprotein E (ApoE) genotype is one of the most important risk factors for a number of ageassociated diseases, 13 and the single greatest genetic risk factor for Alzheimer's Disease. 14 ApoE is a component of HDL particles that is involved in mediating HDL functional capacity. 15, 16 Although ApoE is known to be a glycosylated protein, ApoE glycosylation has only been partially characterized. To date, no comprehensive site-specific glycosylation analysis across all detectable glycosylation sites has been obtained for ApoE.
Dietary changes can modify HDL cholesterol efflux capacity, 17 and anti-inflammatory capacity (reviewed in 18 ), however, it is not clear whether diet alters HDL glycoprofiles or whether HDL glycoprofiles are also associated with HDL's cholesterol efflux capacity. The half-life of ApoA-I, the main 4 protein constituent of HDL, is approximately 4 days, 19 and we previously showed that the HDL lipidome is drastically remodeled by diet in 4 days. 20 Hence, we postulated that if there is an effect of diet on HDL glycoprofiles it may be visible within this time frame.
In this pilot study, we hypothesized that a 4-day dietary intervention period measurably alters HDL site-specific glycoprofiles and HDL functionality. Specifically, the effects of consuming a fast food (FF) diet vs. a Mediterranean (Med) diet were compared to broadly test the hypothesis that large-scale shifts in overall dietary pattern in the short-term can alter HDL glycoprofiles and functionality. The FF arm of the study was designed to reflect a typical Western diet, which is enriched in red meat, simple sugars, fat, saturated fat, and cholesterol, and low in fresh fruits, vegetables and fiber. [21] [22] [23] [24] [25] The Med arm of the study was designed to reflect what is currently widely thought to be a healthy diet enriched in fresh fruits, vegetables, fiber, monounsaturated fat, and polyunsaturated fat, particularly omega-3 fatty acids. [26] [27] [28] [29] [30] [31] HDL function and site-specific glycoprofiles in response to the two dietary patterns were assessed and compared. 5
MATERIALS AND METHODS

Study design and subjects
Ten healthy human subjects (5 male and 5 female) were recruited into a randomized order, crossover study. Each subject was given both FF and Med diet for 4 days in duration in randomized order with a 4-day washout between treatments. The study dietary plan was balanced for each participant's daily caloric requirements calculated using the Harris-Benedict equation. The study foods for the Med diet were purchased at a local grocery store and prepared for participants to consume at home, while the foods for the FF diet were purchased from a local fast food restaurant. An overnight fasted blood draw was taken from the antecubital vein by a licensed phlebotomist, and anthropometric measurements were taken on the first and the morning after the last day of each study arm. Plasma or serum was separated within 1 hour of the blood draw. Samples were aliquoted immediately and stored at -80°C.
One sample was sent for a lipid panel test to the University of California Davis Medical Center pathology lab.
Study subjects were 18-25 years old, non-smokers, with BMI ranging from 21.2 to 32.9 kg/m 2 .
Subjects were free from any disease diagnoses including anemia, diabetes, thyroid disease, metabolic syndrome, cancer, and cardiovascular diseases. Subjects with extreme dietary or exercise patterns, or taking medications or supplements that alter lipoproteins were excluded from the study. The study was approved by the University of California Davis Institutional Review board and registered at clinicaltrials.gov (NCT03205254).
Diet
On the FF arm, depending on the participant's calculated caloric requirement, 1 or 2 frosted strawberry pop-tarts were given for breakfast, and different hamburgers with or without fries were assigned to subjects for lunch and dinner, with soda consumed ad libitum. On the Med arm, breakfast included high fiber cereal in 1% milk with one small banana. Lunch was a study salad with canned tuna 6 or chicken, while dinner was minestrone soup, multigrain blend, tomato basil marinara, mixed vegetables, and extra virgin olive oil (EVOO) adjusted to the calorie level. Almonds and other dried fruits and nuts were provided as snacks between meals according to the prescribed calorie level. The snacks on the Med diet were provided to meet each individual's daily calorie requirement and to maintain the FF and Med arms isocaloric. The study diet menu for FF and Med at the 2000 kcals/day level is shown in Supplemental Table S1.
HDL isolation
A 2-step density based sequential flotation ultracentrifugation method was used to isolate HDL particles as previously described. 12 Two ml plasma was adjusted using a concentrated potassium bromide (KBr) solution (density 1.340 g/mL) to a density of 1.063 g/mL, before being underlaid to KBr solution of 1.063 g/mL into an ultracentrifugation tube (OptiSeal, Beckman Coulter). A 2 mL supernatant was removed after an ultracentrifugation spin at 110,000 rpm for 3 hours and 10 minutes. The HDLcontaining bottom layer was then adjusted to a density of 1.21 g/mL by adding the same concentrated KBr solution, followed by underlaying to KBr solution of 1.21 g/mL in two ultracentrifugation tubes. After the second ultracentrifugation spin at 110,000 rpm for 3 hours and 20 minutes, 1 mL supernatant of HDL fraction from each ultracentrifugation tube was combined and dialyzed twice using Amicon Ultra-4,MWCO 10 KDa filter units. The HDL fraction was reconstituted in either LC-MS water for glycoproteomics and ELISA assays, or PBS for functional assays. Samples were stored in -80°C until analysis. All KBr solutions were freshly prepared and verified using a densitometer (Mettler Toledo, Columbus, OH). Ultracentrifugation was performed on a Beckman Optima MAX-TL equipped with a TLA-110 fixed-angel roter (Beckman Coulter, k factor 13.04)
Apolipoprotein E glycoprofile
The ApoE glycoprofile was identified using purified Apo E standard from human plasma obtained from Sigma-Aldrich (St. Louis, Missouri). The proteins were digested and analyzed as previously described. 10 In brief, proteins were denatured with dithiothreitol and alkylated with iodoacetamide. The denatured proteins were then digested with 2μg of sequencing grade trypsin (Promega, Madison, WI) for 18 h at 37°C. The protein tryptic digest was analyzed on a nanoLC Q-Exactive Orbitrap MS platform (Thermo Scientific, Waltham, MA) equipped with a 75 μm × 150 mm Magic C18 reversed phase column.
Peptides and glycopeptides were identified using Byonic software (Protein Metrics, Inc.) set to a precursor and fragment mass tolerance of 10 ppm and a false discovery rate of < 1%. Only peptides and glycopeptides with a log probability greater than 2 were considered.
HDL glycoproteomics
The following glycoproteins were monitored and both the glycoprotein and the site-specific glycosylation quantities were determined for ApoE, apolipoprotein C-III (ApoC-III), alpha-1-antitrypsin (A1AT), and alpha-2-HS-glycoprotein (A2HSG, or fetuin A). Serum amyloid A (SAA) 1 and 2, which are the inducible and pro-inflammatory isoforms, are not glycosylated, thus only the protein quantity was measured. The mixture of peptides and glycopeptides was analyzed using an Agilent 1290 infinity LC system coupled with an Agilent 6490 triple quadrupole (QQQ) mass spectrometer (Agilent technology, Santa Clara, CA) using a previously published method. 10 Briefly, isolated HDL samples and protein standards were digested using trypsin and then separated on the Agilent eclipse plus C18 (RRHD 1.8 μm, BioTek, VT), with the emission and excitation wavelengths of 482 and 515 nm, respectively. The percentage cholesterol efflux is calculated as below.
HDL ApoA-I and Cholesterol Efflux Assay
% Chol Efflux = Fluorescence Intensity of Media Fluorecence Intensity of Cell Lysate + Media × 100%
HDL Immunomodulatory Assay
Isolated HDL from each subject was supplemented into the media (RPMI 1640, 10% FBS, 1× PSG) of primary PBMCs (4×10 4 cells/well) at a normalized concentration of 1 mg/mL of protein for 1 hour before exposing the HDL-cell mixture to 20 μg/mL of citrullinated fibrinogen immune complexes (cFb-IC)
as an inflammatory stimulant specific to the Fc-γ receptor pathway. 32 Cells were incubated for 18 hours to allow time for cytokine secretion after which the supernatants of each reaction were collected and TNF-α was measured by ELISA (Peprotech, Rocky Hill, NJ). Additionally, a positive control reaction consisting of PBMCs stimulated with cFb-ICs without any added HDL and a negative control consisting of unstimulated PBMCs were used to assess the effects of HDL on PBMC cytokine secretion. The % TNF-α suppression was calculated as below:
% TNF-α Suppression = (1 -TNFα (ng/mL) in Sample TNFα (ng/mL) in Positive Control ) ×100%
Statistical Analysis
The total amount of each protein (ApoE, ApoC-III, A1AT, A2HSG, and SAA) was quantified as the total intensity for the unglycosylated peptide with the highest response (i.e. indicator peptide) divided by the total protein amount in the isolated HDL fraction measured by nanodrop. For the glycoform quantitation, the intensity of each glycopeptide was normalized to the intensity of its corresponding unglycosylated indicator peptide.
A differential abundance test was applied to the normalized site-specific glycosylation data using a mixed linear model, with the R package, limma. 33 Multiple test correction was performed on the pvalues using the Benjamini-Hochberg method whenever more than 10 variables were tested. The same 10 linear model was also applied on HDL cholesterol efflux, TNF-α suppression, and HDL ApoA-I level. Data were log2 transformed before linear model analysis and the shapiro.test function in R was used to perform the Shapiro-Wilk test of normality. The Pearson's correlation test was applied to find the correlation between different variables.
RESULTS
Baseline Characteristics and Dietary Records
All anthropometric values, blood pressure, and blood lipid levels were in the expected ranges and did not change significantly across the study period ( Table 1 ). The BMIs showed that subjects were normal to slightly overweight. Summary data from the three-day diet records from baseline and during the two study treatments are listed in Supplemental Table S3 . The total calorie intake of each subject was relatively equivalent to their baseline level. The daily calorie intake at baseline was not statistically significantly different from FF (p = 0.506) or Med (p=0.277). Carbohydrate intake was not significantly different between the two treatments. 
HDL ApoA-I Content and Functional Measures
The average HDL ApoA-I concentration measured in this study population was 156.96 (±28.81) mg/dL. The change in HDL ApoA-I was statistically significant by mixed linear model analysis (p = 0.015 (Figure 1-A) ). The increase after FF was not statistically significant, but the decrease after Med was (p = before and after Med) were significantly affected by either of the dietary interventions (Figure 1-B&C) .
HDL cholesterol efflux capacity was positively associated with TNF-α suppression (rho = 0.304, p = 0.057, 
HDL Glycopeptides
Eighty-six glycopeptides were detected across the 4 measured proteins across all samples. ApoE was added to the existing MRM site-specific glycosylation method described previously. 10 The two most abundant ApoC-III glycans, ApoC3_74_O_1102 and ApoC3_74_O_2230, were differentially affected by diet. The disialylated glycopeptide ApoC3_74_O_1102 decreased after FF and increased after Med whereas the non-sialylated glycopeptide ApoC3_74_O_2230 increased after FF and decreased after Med (unadjusted p = 0.001 and 0.021 respectively, Figure 1-E&F) . However, they did not remain statistically significant after adjustment for multiple testing (adjusted p = 0.089, adjusted).
Supplemental Table S4
lists all glycopeptides with their relative abundance before and after FF and Table S5 ).
Although most HDL glycopeptides were not affected differently by diet, many of them were 
DISCUSSION
There is agreement that improving HDL functional capacity is a desirable strategy for preventing disease and improving outcomes associated with dyslipidemia. However, it is not at all clear how to improve HDL functional capacity. Since diet can modify HDL functional capacity by altering its composition, and at the same time, is a major potential source of background variance in free-living individuals, we set out to define the impact of diet on HDL composition and function at the timescale of 4 days. We were interested in the effects of diet on the quantities and glycoprofiles of key HDLassociated proteins, and whether HDL glycoprofiles are associated with HDL functional capacity. In particular, ApoE is of great interest due to the known associations with Alzheimer's and cardiovascular disease risks. 34, 35 ApoE structure is also known to affect lipoprotein metabolism. 36, 37 It is not yet clear how the glycosylation of ApoE affects its structure and function in the context of HDL particles, though it has already been shown that ApoE desialylation reduces binding to HDL and increases binding to VLDL. 38 ApoE does not contain the consensus amino acid sequence (NX(T/S/C)) for N-linked glycosylation, and instead is O-glycosylated with mucin-type glycans at Thr 194 which is not essential for ApoE secretion. 39 It was also confirmed that the Thr 212 is a glycosylation site by are recent study. 40 ApoE secreted by macrophages isolated from PBMCs of a single donor with ApoE3/E3 genotype had 8 different non-, mono-, and di-sialylated glycoforms at site Thr 194 , and 3 putative new sites were identified at Ser 290 , Thr 289 and Ser 296 . 41 In this study we report for the first time an additional 4 Oglycosylation sites in HDL-associated ApoE, with glycans attached ranging from simple GlcNAc to biantennary structures containing both sialic acid and fucose. Future studies are needed to determine the exact sites of glycan attachment in the three putative glycosylation sites found in this study.
The glycoprofile of ApoE was not affected by short-term diet in this study. The glycans attached to A1AT and A2HSG were also not changed in response to diet at the time scale tested in this study. Two
ApoC-III sialylated glycans were changed by diet but did not remain statistically significant after adjustment for multiple testing. In our previous study, the glycan ApoC3_74_O_1102, which decreased after FF and increased after Med in this study, was found to be 2-fold higher in HDL compared to plasma, 10 and was elevated in hemodialysis patients, but decreased in MetS patients compared to healthy human controls. 12 Although the glycan ApoC3_74_O_2230, which increased after FF and decreased after Med in this study, was not detected in our previous study, another non-sialylated ApoC-III glycan, ApoC3_74_O_0300, was found to be decreased in hemodialysis patients and elevated in MetS patients. 12 Di-sialylated ApoC-III is enriched in small dense LDL in hemodialysis patients with dyslipidemia, 42 and was found to be reduced across lipoprotein classes in MetS patients. 43 This suggests that sialylation of HDL-associated ApoC-III is altered by underlying physiological or disease state as well as by short-term dietary changes.
It has been shown previously that HDL ApoA-I content is associated with cholesterol efflux capacity. 44 However, although HDL ApoA-I content decreased on the Med diet and increased on the FF diet, neither of the two HDL functional capacities tested were significantly altered in response to the diets. It is not clear whether the lack of effect of diet on HDL cholesterol efflux capacity, capacity to suppress TNF-α secretion in cFb-IC stimulated monocytes, and HDL associated ApoE, A1AT and A2HSG content and glycoprofiles is due to the study duration, the sample size, or whether there is truly no effect of dietary changes of the type tested in this study on these HDL compositional and functional measures. Future studies are needed to determine the longer-term effects of diet, the effects of individual dietary components, and the effects of diet in larger cohorts of individuals.
Despite the lack of effect of short-term diet change, the results from this study suggest that the glycoprofiles of HDL-associated proteins are highly correlated with both cholesterol efflux and immunomodulatory capacity. The functional role of glycosylation of HDL proteins is not yet known.
Multiple glycopeptides on A1AT, A2HSG and ApoE were positively correlated, whereas ApoC-III glycopeptides were generally negatively correlated with both HDL functional measures. In a previous 19 study we found that HDL that suppressed IL-6 production in LPS-stimulated monocytes were enriched in di-sialylated A2HSG, particularly A2HSG_176_N_5402, 12 and in this study we similarly found a positive correlation between A2HSG_176_N_5402 and both HDL functional measures. We previously found that both 5402 and 5412 attached at multiple sites of A1AT were decreased in HDL that suppressed IL-6 production in LPS-stimulated monocytes, 12 whereas in this study we found that glycopeptides containing these di-sialylated glycans were positively correlated with cholesterol efflux capacity and the capacity to 20
CONCLUSION
In this study we report for the first time that ApoE has 4 additional O-glycosylation sites that were not reported previously, and describe an MRM method for profiling ApoE glycosylation. Whereas consuming two very different diets for 4 days did not affect the glycoprofile of ApoE, A1AT, or A2HSG associated with HDL particles, the quantities of these proteins, or the two HDL functional capacities we measured, HDL-associated ApoC-III sialylation and quantity of ApoA-I were altered. Our results suggest that overall HDL glycoproteomic composition may be more highly influenced by factors other than diet in the short term and thus may be more indicative of longer-term processes and/or disease conditions, however, ApoC-III sialylation may be more directly responsive to short-term dietary change. Our results also revealed that HDL functionality is strongly associated with HDL glycoproteomic composition, and the mechanisms and implications of this association need to be further studied in future studies.
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